消息發布

美國疾病控制中心出版之Journal of Emerging Infectious Diseases報導 UBI之SARS 抗體之檢測試劑之開發成果

UBI (United Biomedical, Inc) of Hauppauge, NY USA and its subsidiary, UBI-Asia of Hsin Chu, Taiwan, have developed the first peptide-based diagnostic test for SARS. The UBI/UBI-Asia test uses non-biohazardous synthetic peptides to detect anti-SARS antibodies in the blood of people who have been exposed to the virus. In a report expedited for publication in the September 2004 issue of Emerging Infectious Diseases, a group led by Dr. Po-Ren Hsueh of National Taiwan University College of Medicine found that the UBI/UBI-Asia SARS test kit detected antibodies to SARS virus in the blood of all patients with confirmed SARS.

The peptide-based SARS test also detected antibodies in healthy hospital personnel from hospitals in Taiwan that treated SARS patients. This result suggests that the new test can detect a history of SARS infection even in cases where symptoms were not apparent. Dr. Hsueh's article has already published in Emerging Infectious Diseases Vol. 10, No. 9, September 2004. (www.cdc.gov/eid)

This blood test for SARS will provide public health authorities with a safe and convenient means to trace back to the sources of a SARS epidemic, to prevent future outbreaks.


Contact:
Ms. Jasmine Lin
Public Relations
Tel: 886-3-5984151
Fax: 886-3-5981173
jasmine@mail.ubiasia.com.tw
Web Page: www.ubiasia.com.tw
回上頁